Innovative Medicines Initiative (IMI) 2 Call 13: Indicative Topics Published

IMI 2 has just published a list of indicative topics for the call 13 which is foreseen to be launched before the end of the year.

The following topics are under consideration for inclusion in future IMI calls for proposals:

- Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
- Genome-environment interactions in inflammatory skin disease
- The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
- Mitochondrial dysfunction in neurodegeneration
- Support and coordination action for the projects of the neurodegeneration area of the Innovative Medicines Initiative
- A sustainable European induced pluripotent stem cell platform
- Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice
- Human tumour microenvironment immunoprofiling
- CONCEPTION - continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
- Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
- Translational safety biomarker pipeline (TRANSBIOLINE): enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
- Federated and privacy-preserving machine learning in support of drug discovery
- Pilot programme on a clinical compound bank for repurposing. This programme includes the following topics: Cardiovascular diseases and diabetes, Respiratory diseases, Neurodegenerative diseases and Rare/orphan diseases

Source: IMI2

OTOSTEM News

This section of our website will keep you posted with our most relevant news and information.

You can subscribe to our RSS feed by clicking on the link below.
The OTOSTEM project has received funding from the European Community's Seventh Framework Programme under grant agreement No. 603029.